Portfolio company KalVista acquired by Chiesi

Summary by AI BETAClose X

International Biotechnology Trust PLC announced that its portfolio company, KalVista Pharmaceuticals, will be acquired by Chiesi Farmaceutici for $27 per share in cash, representing a 36% premium to KalVista's 30-day volume-weighted average share price. As of April 28, KalVista constituted 1.6% of IBT's Net Asset Value. This marks the fifth acquisition within IBT's portfolio in 2026, highlighting strong M&A activity in the biotech sector driven by large pharmaceutical companies seeking to bolster their pipelines. The updated valuation of IBT's KalVista holding will be reflected in its NAV as of April 29.

Disclaimer*

UK 100

Latest directors dealings